{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T21:22:06Z","timestamp":1794345726361,"version":"4.9.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.clinre.2026.102931","type":"journal-article","created":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T22:13:04Z","timestamp":1790547184000},"page":"102931","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A practical approach to abnormal liver enzymes in pediatric IBD in the biologic and targeted therapy era"],"prefix":"10.1016","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-7068-3561","authenticated-orcid":false,"given":"Zara","family":"Zaidi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8159-387X","authenticated-orcid":false,"given":"Christopher","family":"Hartley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Cesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wikrom","family":"Karnsakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.clinre.2026.102931_bib0001","doi-asserted-by":"crossref","DOI":"10.4254\/wjh.v17.i12.114084","article-title":"Drug-induced liver injury in inflammatory bowel disease: challenges in diagnosis and monitoring","volume":"17","author":"Singh","year":"2025","journal-title":"World J Hepatol"},{"issue":"2","key":"10.1016\/j.clinre.2026.102931_bib0002","first-page":"162","article-title":"Retrospective study of idiosyncratic drug-induced liver injury from infliximab in an inflammatory bowel disease cohort: the IDLE study","volume":"33","author":"Worland","year":"2020","journal-title":"Ann Gastroenterol"},{"key":"10.1016\/j.clinre.2026.102931_bib0003","unstructured":"Untaroiu, A. When medicine turns toxic: the hepatotoxic potential of common drugs. Liver Fellow Network web site. https:\/\/www.aasld.org\/liver-fellow-network\/core-series\/back-basics\/when-medicine-turns-toxic-hepatotoxic-potential-common. Accessed May 12, 2026."},{"issue":"5","key":"10.1016\/j.clinre.2026.102931_bib0004","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/clpt.2013.16","article-title":"The liver toxicity knowledge base: a systems approach to a complex end point","volume":"93","author":"Chen","year":"2013","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.clinre.2026.102931_bib0005","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/clpt.2011.58","article-title":"Case definition and phenotype standardization in drug-induced liver injury","volume":"89","author":"Aithal","year":"2011","journal-title":"Clin Pharmacol Ther"},{"issue":"10538","key":"10.1016\/j.clinre.2026.102931_bib0006","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/S0140-6736(25)02582-6","article-title":"Primary sclerosing cholangitis","volume":"407","author":"von Seth","year":"2026","journal-title":"lancet"},{"issue":"9","key":"10.1016\/j.clinre.2026.102931_bib0007","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.cgh.2006.06.015","article-title":"Step-up versus top-down: application of new biological agents in pediatric inflammatory bowel disease","volume":"4","author":"Faubion","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.clinre.2026.102931_bib0008","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjag084","article-title":"Management of pediatric crohn's disease: an ECCO-ESPGHAN guideline update","volume":"20","author":"Shouval","year":"2026","journal-title":"J Crohn's Colitis"},{"issue":"3","key":"10.1016\/j.clinre.2026.102931_bib0009","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/jpn3.70097","article-title":"Management of paediatric ulcerative colitis, part 1: ambulatory care-an updated evidence-based consensus guideline from the european society of paediatric gastroenterology, hepatology and nutrition and the european crohn's and colitis organisation","volume":"81","author":"Wine","year":"2025","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"5","key":"10.1016\/j.clinre.2026.102931_bib0010","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.clinre.2026.102931_bib0011","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.cgh.2014.07.062","article-title":"Risk of drug-induced liver injury from tumor necrosis factor antagonists","volume":"13","author":"Bj\u00f6rnsson","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.clinre.2026.102931_bib0012","doi-asserted-by":"crossref","DOI":"10.1007\/s10620-026-09854-1","article-title":"Risk of autoimmune hepatitis among patients with inflammatory bowel disease treated with infliximab: a retrospective cohort study using a national database","author":"Almusabeh","year":"2026","journal-title":"Dig Dis Sci"},{"issue":"8","key":"10.1016\/j.clinre.2026.102931_bib0013","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/apt.16060","article-title":"Long-term safety of vedolizumab for inflammatory bowel disease","volume":"52","author":"Loftus","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinre.2026.102931_bib0014","series-title":"VedolizumabLiverTox: clinical and research information on drug-induced liver injury","year":"2012"},{"issue":"1","key":"10.1016\/j.clinre.2026.102931_bib0015","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/apt.14794","article-title":"Long-term efficacy and safety of ustekinumab for crohn's disease through the second year of therapy","volume":"48","author":"Sandborn","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinre.2026.102931_bib0016","series-title":"UstekinumabLiverTox: clinical and research information on drug-induced liver injury","year":"2012"},{"issue":"21","key":"10.1016\/j.clinre.2026.102931_bib0017","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1056\/NEJMoa2212728","article-title":"Upadacitinib induction and maintenance therapy for crohn's disease","volume":"388","author":"Loftus","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinre.2026.102931_bib0018","series-title":"UpadacitinibLiverTox: clinical and research information on drug-induced liver injury","year":"2012"},{"key":"10.1016\/j.clinre.2026.102931_bib0020","series-title":"LiverTox: clinical and research information on drug-induced liver injury","article-title":"Infliximab","author":"Hoofnagle","year":"2012"},{"key":"10.1016\/j.clinre.2026.102931_bib0021","unstructured":"Humira\u00ae (adalimumab) [package insert]. abbott laboratories.; published 2011. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/125057s0276lbl.pdf."},{"key":"10.1016\/j.clinre.2026.102931_bib0022","series-title":"LiverTox: clinical and research information on drug-induced liver injury","article-title":"Adalimumab","author":"Hoofnagle","year":"2012"},{"key":"10.1016\/j.clinre.2026.102931_bib0025","series-title":"LiverTox: clinical and research information on drug-induced liver injury","article-title":"Certolizumab pegol","author":"Hoofnagle","year":"2012"},{"key":"10.1016\/j.clinre.2026.102931_bib0026","series-title":"LiverTox: clinical and research information on drug-induced liver injury","article-title":"Golimumab","author":"Hoofnagle","year":"2012"},{"key":"10.1016\/j.clinre.2026.102931_bib0030","unstructured":"Tremfya\u00ae (guselkumab) [package insert]. janssen biotech, inc.; published 2026."},{"key":"10.1016\/j.clinre.2026.102931_bib0031","series-title":"GuselkumabLiverTox: clinical and research information on drug-induced liver injury","year":"2012"},{"key":"10.1016\/j.clinre.2026.102931_bib0032","series-title":"RisankizumabLiverTox: clinical and research information on drug-induced liver injury","year":"2012"},{"key":"10.1016\/j.clinre.2026.102931_bib0034","series-title":"TofacitinibLiverTox: clinical and research information on drug-induced liver injury","year":"2012"},{"key":"10.1016\/j.clinre.2026.102931_bib0038","series-title":"LiverTox: clinical and research information on drug-induced liver injury","article-title":"Mercaptopurine","author":"Hoofnagle","year":"2012"},{"key":"10.1016\/j.clinre.2026.102931_bib0039","series-title":"LiverTox: clinical and research information on drug-induced liver injury","article-title":"Azathioprine","author":"Hoofnagle","year":"2012"},{"key":"10.1016\/j.clinre.2026.102931_bib0041","series-title":"MethotrexateLiverTox: clinical and research information on drug-induced liver injury","year":"2012"},{"key":"10.1016\/j.clinre.2026.102931_bib0043","series-title":"LiverTox: clinical and research information on drug-induced liver injury","article-title":"Natalizumab","author":"Hoofnagle","year":"2012"},{"key":"10.1016\/j.clinre.2026.102931_bib0044","series-title":"MesalamineLiverTox: clinical and research information on drug-induced liver injury","year":"2012"},{"key":"10.1016\/j.clinre.2026.102931_bib0045","series-title":"LiverTox: clinical and research information on drug-induced liver injury","article-title":"Sulfasalazine","author":"Hoofnagle","year":"2012"},{"issue":"4","key":"10.1016\/j.clinre.2026.102931_bib0047","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1097\/MPG.0000000000001492","article-title":"Hepatic issues and complications associated with inflammatory bowel disease: a clinical report from the NASPGHAN inflammatory bowel disease and hepatology committees","volume":"64","author":"Saubermann","year":"2017","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"1","key":"10.1016\/j.clinre.2026.102931_bib0048","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/j.gastro.2014.10.039","article-title":"American gastroenterological association institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy","volume":"148","author":"Reddy","year":"2015","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.clinre.2026.102931_bib0049","doi-asserted-by":"crossref","DOI":"10.1111\/jvh.70152","article-title":"Hepatitis E infection in patients with inflammatory bowel diseases: a systematic review and meta-analysis","volume":"33","author":"Kogias","year":"2026","journal-title":"J Viral Hepat"},{"issue":"3","key":"10.1016\/j.clinre.2026.102931_bib0050","doi-asserted-by":"crossref","DOI":"10.3390\/jpm16030139","article-title":"Precision medicine in inflammatory bowel disease: the emerging role of metabolic dysfunction","volume":"16","author":"Kotha","year":"2026","journal-title":"J Pers Med"},{"issue":"13","key":"10.1016\/j.clinre.2026.102931_bib0051","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1016\/j.cgh.2015.06.020","article-title":"Risk of acute liver failure in patients with drug-induced liver injury: evaluation of hy's law and a new prognostic model","volume":"13","author":"Lo Re","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.clinre.2026.102931_bib0052","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/0895-4356(93)90101-6","article-title":"Causality assessment of adverse reactions to drugs\u2013I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries","volume":"46","author":"Danan","year":"1993","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"10.1016\/j.clinre.2026.102931_bib0053","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1053\/j.gastro.2024.11.008","article-title":"AGA clinical practice guideline on the prevention and treatment of hepatitis B virus reactivation in at-risk individuals","volume":"168","author":"Ali","year":"2025","journal-title":"Gastroenterology"},{"issue":"42","key":"10.1016\/j.clinre.2026.102931_bib0054","doi-asserted-by":"crossref","first-page":"7327","DOI":"10.3748\/wjg.v19.i42.7327","article-title":"Hepatobiliary manifestations in inflammatory bowel disease: the gut, the drugs and the liver","volume":"19","author":"Rojas-Feria","year":"2013","journal-title":"World J Gastroenterol"},{"issue":"Suppl 1","key":"10.1016\/j.clinre.2026.102931_bib0055","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1038\/ajg.2011.58","article-title":"An evidence-based systematic review on medical therapies for inflammatory bowel disease","volume":"106","author":"Talley","year":"2011","journal-title":"Am J Gastroenterol"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740126001774?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740126001774?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T20:35:57Z","timestamp":1794342957000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740126001774"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":42,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S2210740126001774"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2026.102931","relation":{},"ISSN":["2210-7401"],"issn-type":[{"value":"2210-7401","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A practical approach to abnormal liver enzymes in pediatric IBD in the biologic and targeted therapy era","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2026.102931","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102931"}}